Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus

Enadenotucirev is an oncolytic group B adenovirus identified by a process of bio-selection for the ability to selectively propagate in and rapidly kill carcinoma cells. It is resistant to inactivation by human blood components, potentially enabling intravenous dosing in patients with metastatic canc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Mol Ther Oncolytics
Main Authors: Illingworth, Sam, Di, Ying, Bauzon, Maxine, Lei, Janet, Duffy, Margaret R., Alvis, Simon, Champion, Brian, Lieber, André, Hermiston, Terry, Seymour, Len W., Beadle, John, Fisher, Kerry
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Gene & Cell Therapy 2017
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5415321/
https://ncbi.nlm.nih.gov/pubmed/28480328
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2017.03.003
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados